R1	Has_value Arg1:T2 Arg2:T1	
R2	Has_value Arg1:T6 Arg2:T7	
R3	AND Arg1:T6 Arg2:T8	
R4	Has_value Arg1:T8 Arg2:T9	
R5	Subsumes Arg1:T5 Arg2:T6	
R6	Has_qualifier Arg1:T4 Arg2:T5	
*	OR T10 T11
*	OR T13 T16 T14 T15
R7	AND Arg1:T18 Arg2:T17	
R8	Has_multiplier Arg1:T13 Arg2:T12	
R9	AND Arg1:T10 Arg2:T13	
*	OR T10 T18
R10	Has_temporal Arg1:T25 Arg2:T26	
*	OR T22 T24
*	OR T28 T29
R11	Has_temporal Arg1:T23 Arg2:T30	
R12	Has_qualifier Arg1:T28 Arg2:T23	
R13	Has_qualifier Arg1:T22 Arg2:T25	
*	OR T22 T28
R14	AND Arg1:T32 Arg2:T22	
*	OR T41 T44 T43 T42 T45
R15	Subsumes Arg1:T40 Arg2:T41	
*	OR T48 T49
R16	Subsumes Arg1:T52 Arg2:T51	
R17	Has_qualifier Arg1:T53 Arg2:T54	
R18	Subsumes Arg1:T57 Arg2:T58	
T1	Value 9 19	= 18 years
T2	Person 23 26	age
T3	Non-query-able 28 153	Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
T4	Condition 180 182	UC
T5	Qualifier 187 205	moderate-to-severe
T6	Measurement 237 247	Mayo score
T7	Value 251 255	6-12
T8	Measurement 265 284	endoscopic subscore
T9	Value 285 287	=2
T10	Condition 306 325	inadequate response
T11	Condition 337 355	failed to tolerate
T12	Multiplier 357 366	1 or more
T13	Drug 408 431	oral 5-aminosalicylates
T14	Drug 433 453	oral corticosteroids
T15	Drug 455 473	azathioprine (AZA)
T16	Drug 482 504	6-mercaptopurine (6MP)
T17	Drug 509 523	corticosteroid
T18	Condition 524 533	dependent
T19	Non-representable 534 611	(ie, an inability to taper corticosteroids without recurrence of UC symptoms)
T22	Drug 649 672	oral 5-aminosalicylates
T24	Drug 676 691	corticosteroids
T25	Qualifier 710 721	stable dose
T26	Temporal 722 758	for at least 2 weeks before baseline
T28	Drug 783 786	AZA
T29	Drug 794 797	6MP
T23	Qualifier 816 827	stable dose
T30	Temporal 828 864	for at least 4 weeks before baseline
T32	Procedure 636 643	treated
T34	Non-representable 866 967	Patients were required to maintain stable doses of their concomitant UC medications during the study.
T35	Pregnancy_considerations 969 1140	Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR
T36	Pregnancy_considerations 1142 1272	Surgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR
T37	Pregnancy_considerations 1274 1385	Postmenopausal women with postmenopausal defined as permanent cessation >1 year of previously occurring menses.
T38	Pregnancy_considerations 1387 1532	Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.
T39	Non-representable 1534 1607	Subjects have following investigations within 1 month prior to enrolment.
T40	Procedure 1609 1623	Routine bloods
T41	Procedure 1634 1637	U&E
T42	Procedure 1639 1642	FBC
T43	Procedure 1644 1648	LFTs
T44	Procedure 1650 1676	inflammatory markers (CRP)
T45	Procedure 1681 1688	albumin
T47	Non-representable 1708 1748	Medical history, concomitant medications
T48	Procedure 1750 1800	Intradermal reaction to Tuberculin (PPD skin test)
T49	Procedure 1804 1884	Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA)
T50	Temporal 1573 1606	within 1 month prior to enrolment
T51	Procedure 1900 1911	chest X-Ray
T52	Procedure 1886 1898	TB screening
T53	Procedure 1951 1968	Stool examination
T54	Qualifier 1969 2022	for enteric pathogens including Clostridium difficile
T55	Non-query-able 2054 2070	Informed consent
T56	Non-representable 2024 2052	Inclusion/exclusion criteria
T57	Procedure 2072 2082	Mayo score
T58	Procedure 2094 2107	sigmoidoscopy
T59	Procedure 2180 2203	abdominal circumference
T60	Procedure 2169 2175	height
T61	Procedure 2158 2164	weight
